Study summary

The purpose of this study was to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517.

This study also evaluated the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.

Additional Study Details

Phase
Phase 1/Phase 2
Product
Type
Interventional
Masking
None (Open Label)
Enrollment number
43
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English
Protocol
Available Language(s): English
Statistical Analysis Plan (SAP)
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)? Contact us by filling out your information to the right and we’ll respond to you.

  • A patient
  • A caregiver
  • A parent
  • A healthcare provider
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site JP81004
    Maebashi, Gunma, Japan
    Completed
    Site JP81007
    Kobe, Hyogo, Japan
    Completed
    Site JP81008
    Okayama, Okayama, Japan
    Completed
    Site JP81005
    Nagoya, Aichi, Japan
    Completed
    Site JP81001
    Shinagawa, Tokyo, Japan
    Completed
    Site JP81002
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP81009
    Yoshida-gun, Fukui, Japan
    Completed
    Site JP81010
    Gifu, Gifu, Japan
    Completed
    Site JP81011
    Osaka, Osaka, Japan
    Completed
    Site JP81013
    Isehara, Kanagawa, Japan
    Completed
    Site JP81012
    Osaka, Osaka, Japan
    Completed
    Site JP81016
    Matsuyama, Ehime, Japan
    Withdrawn
    Site JP81014
    Bunkyo, Tokyo, Japan
    Withdrawn
    Gabrail Cancer Center
    Canton, OH, United States, 44718
    Completed
    Memorial Healthcare System-West
    Pembroke Pines, FL, United States, 33028
    Completed
    City of Hope
    Duarte, CA, United States, 91010
    Completed
    Site JP81017
    Sendai, Miyagi, Japan
    Withdrawn
    Site JP81015
    Yokohama, Kanagawa, Japan
    Withdrawn
    University of Chicago Comprehensive Cancer Center
    Chicago, IL, United States, 60637
    Completed
    NYU Langone Health
    New York, NY, United States, 10016
    Withdrawn
    Northside Hospital Cancer Institute
    Atlanta, GA, United States, 30342
    Withdrawn
    MD Anderson Cancer Center
    Houston, TX, United States, 77030
    Withdrawn
    UAB O’Neal Comprehensive Cancer Center
    Birmingham, AL, United States, 35233

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?